Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas

NCT07183280 · tracked via the Priya Life Science China tracker

Sponsor

Fudan University

Phase

Observational

Started

2025-09-01

Last updated

2025-09-19

Condition(s) studied

Solid Pseudopapillary Neoplasm of the Pancreas

Investigational drug(s) / intervention(s)

operation

operation: Enucleation, spleen-preserving distal pancreatectomy, or duodenum-preserving pancreatic head resection, etc

Study summary

To establish and maintain a reliable multicenter real-world database for pancreatic SPN, providing high-quality data and evidence-based support for clinical/translational research.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * No restrictions on age, gender, or performance status; * Pathologically/cytologically confirmed SPN; * Compliance with follow-up requirements; Exclusion Criteria: * Non-neoplastic pancreatic lesions; * Non-pancreatic primary tumors; * Non-compliance with follow-up;

Primary outcome measure(s)

Overall survival — 12 month
OS: OS of subjects from recruiting to the time of death from any cause

Trial sites (1)

Facility	City	Region	Status
Shanghai Cancer Center	Shanghai	Special Administrative Region	Recruiting

More Fudan University trials in China

The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast Cancer Starting soon

Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer Starting soon

an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer Active, not recruiting

Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma Starting soon

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07183280 on ClinicalTrials.gov ↗ ← All trials in China